New to Meducation?
Sign up
Already signed up? Log In
view moderators

StemCellTransplantation

Category

Www.bmj
1
4

MS patients are in sustained remission after stem cell transplantation, small study finds

Most patients with relapsing remitting multiple sclerosis (MS) who are taking part in a small study of high dose immunosuppressive therapy followed by transplantation of their own haematopoietic stem cells have experienced sustained remission for three years, a study has found.  
bmj.com
over 4 years ago
Www.bmj
0
3

MS patients are in sustained remission after stem cell transplantation, small study finds

Most patients with relapsing remitting multiple sclerosis (MS) who are taking part in a small study of high dose immunosuppressive therapy followed by transplantation of their own haematopoietic stem cells have experienced sustained remission for three years, a study has found.  
feeds.bmj.com
over 4 years ago
Preview
0
0

New drug 'halts disease progression' in patients with hard-to-treat Hodgkin lymphoma

Brentuximab vedotin proved effective in stopping disease progression in patients with hard-to-treat Hodgkin lymphoma when administered straight after stem cell transplantation.  
medicalnewstoday.com
over 4 years ago
Preview
0
6

Role of Allogeneic Stem Cell Transplantation in Adult Patients with Ph-negative Acute Lymphoblastic Leukemia: Abstract & Introduction

Abstract & Introduction: In adults with high-risk ALL treated with intensified pediatric-like protocol, allogeneic stem cell transplantation in first complete remission is associated with a 69.5% 3-year overall survival.  
medscape.org
over 4 years ago
Preview
0
1

Busulfan Plus Melphalan for ASCT in Myeloma

Aiming to improve outcomes in autologous stem cell transplantation in myeloma, a Canadian trial investigates a novel agent for induction.  
medscape.com
about 4 years ago
Preview
0
0

Platelet transfusions to treat bleeding compared with platelet transfusions to prevent bleeding in people with blood cancers receiving intensive treatment | Cochrane

We evaluated the evidence regarding whether giving platelet transfusions to patients with low platelets who are bleeding (therapeutically) is as effective and safe as giving platelet transfusions regularly to prevent bleeding (prophylactically). Our target population was people with blood cancers who were receiving intensive myelosuppressive (causing decreased blood cell production) chemotherapy treatments or stem cell transplantation.  
cochrane.org
about 4 years ago
Preview
0
0

Stem Cell Transplantation in Severe Congenital Neutropenia: An Analysis From the European Society for Blood and Marrow Transplantation: Abstract and Introduction

Abstract and Introduction: Matched donor hematopoietic stem cell transplantation has a good outcome in severe congenital neutropenia, but careful patient selection is needed because of high transplant-related mortality.  
medscape.org
about 4 years ago
Preview
0
0

Different doses of platelet transfusion for preventing bleeding in people with low platelet counts due to treatment-induced bone marrow failure | Cochrane

We evaluated the evidence about whether low-dose platelet transfusions (platelet transfusions containing a lower number of platelets (1.1 x 1011/m2 ± 25%)) given to prevent bleeding in people with low platelet counts were as effective and safe as standard-dose (2.2 x 1011/m2 ± 25%) or high-dose platelet transfusions (platelet transfusions containing a larger number of platelets (4.4 x 1011/m2 ± 25%)) given regularly to prevent bleeding (prophylactically). Our target population was children and adults with blood cancers who were receiving intensive chemotherapy treatments or stem cell transplantation.  
cochrane.org
about 4 years ago
Preview
0
0

Platelet transfusions are used to prevent bleeding in people with low platelet counts due to treatment-induced bone marrow failure | Cochrane

We evaluated the evidence about whether platelet transfusions given to prevent bleeding in people with lower platelet counts (for example 5 x 109/L or below) were as effective and safe as the current standard (10 x 109/L or below), or whether higher platelet count levels (20 x 109/L or below, 30 x 109/L or below, or 50 x 109/L or below) were safer than the current standard (10 x 109/L or below). Our target population was people with blood cancers (for example leukaemia, lymphoma, myeloma) who were receiving intensive (myelosuppressive) chemotherapy treatments or stem cell transplantation.  
cochrane.org
about 4 years ago
Preview
0
0

Use ATG for Stem Cell Transplantation in Hematologic Cancers

In recipients of nonrelated hematopoietic stem cell transplants, rabbit antithymocyte globulin (ATG) is associated with lower rates of chronic graft-vs-host disease. Should it be the standard of care?  
medscape.com
almost 4 years ago
Preview
0
9

“Impressive results” in stem cell treatment for multiple sclerosis

Aggressive immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT) halted clinical relapses and the development of new brain lesions for a prolonged period in most patients with multiple sclerosis (MS) taking part in a small early stage trial, results published in the Lancet have shown.1  
feeds.bmj.com
over 3 years ago
Preview
0
9

“Impressive results” in stem cell treatment for multiple sclerosis

Aggressive immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT) halted clinical relapses and the development of new brain lesions for a prolonged period in most patients with multiple sclerosis (MS) taking part in a small early stage trial, results published in the Lancet have shown.1  
feeds.bmj.com
over 3 years ago
Preview
0
10

“Impressive results” in stem cell treatment for multiple sclerosis

Aggressive immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT) halted clinical relapses and the development of new brain lesions for a prolonged period in most patients with multiple sclerosis (MS) taking part in a small early stage trial, results published in the Lancet have shown.1  
feeds.bmj.com
over 3 years ago
Preview
0
7

“Impressive results” in stem cell treatment for multiple sclerosis

Aggressive immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT) halted clinical relapses and the development of new brain lesions for a prolonged period in most patients with multiple sclerosis (MS) taking part in a small early stage trial, results published in the Lancet have shown.1  
feeds.bmj.com
over 3 years ago